Altamir SCA (LTA.PA) stock: key figures, P/E, revenue and dividend
Financials · France · ISIN FR0000053837
Altamir SCA financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 72.70 m EUR | -71.47 m EUR |
| Gross profit | 30.20 m EUR | -74.02 m EUR |
| Operating income | 28.40 m EUR | -61.45 m EUR |
| Net income | 18.80 m EUR | -61.45 m EUR |
| Diluted EPS – continuing operations | 0.52 EUR | -1.68 EUR |
Full history since 1994, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Altamir SCA
Altamir SCA, formerly known as Altamir Amboise, is a private equity investment arm of Amboise SAS, specializing in both direct and fund of fund investments, small and mid-cap companies. In direct investing, the firm specializes in middle market, buyout and growth capital investments. The firm prefers to invest in high-growth companies, diversified by size and geography. The firm prefers to invest in under-developed divisions of larger corporations. It prefers to invest in private equity funds specializing in growth capital and leverage buyouts investments from Europe, United States and Canada. The firm typically invests in the following sectors like commercial services and supplies, industrial, technology, telco, healthcare services, commercial, professional services, consumer durables and apparel, TMT, digital companies, consumer services, education services, hotel, restaurants, leisure, retail and distribution. It also invests in retail and consumer, business and financial services. In financial services firm seeks to invest in specialized finance, multi-sector holding, diversified financial services. In healthcare, it seeks to focus on companies with strong growth potential in areas such as health services (hospitalization structures, home health care and medical analysis); medical devices; in niche pharmaceutical laboratories; and companies in related activities such as dermo-cosmetics, galenic development, and services and databases for health organizations. The firm seeks to invest in unlisted companies based in Europe, with a particular focus on Belgium, France, Luxembourg, Switzerland, Monaco, Italy, Netherlands, Germany and French-speaking Europe; United States and Canada and in larger emerging markets such as China, India and Brazil. In small and mid-cap companies firm prefers to invest in Continental Europe with a focus in France, Italy and Benelux, & larger size companies in Europe, North America and emerging countries like China, India and Brazil. In small and mid-cap size companies it prefers to inv
More stocks
- Costain Group PLC (COST.L)
- FrankSpeech Network, Inc. (MLMC)
- FIRST FINANCIAL CORP /IN/ (THFF)
- Horng Terng Automation Co., Ltd. (7751.TWO)
- FARMERS NATIONAL BANC CORP /OH/ (FMNB)
- Jiangxi Guoguang Commercial Chains Co Ltd (605188.SS)
- Barings BDC, Inc. (BBDC)
- Odyssey Therapeutics, Inc. Common Stock (ODTX)
- Genuit Group PLC (GEN.L)
- Hunan Er Kang Pharmaceutical (300267.SZ)
- Bloomin' Brands, Inc. (BLMN)
- KELLY SERVICES INC (KELYB)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.